Scisparc grants an exclusive license for the sales of cannamide™ on the amazon marketplace in canada to scisparc nutraceuticals

Tel aviv, israel, june 07, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it entered into a license and distribution agreement with scisparc nutraceuticals inc. ("scisparc nutraceuticals"), a subsidiary in which the company owns approximately a 51% equity interest, pursuant to which it granted scisparc nutraceuticals an exclusive license to sell and market cannamide™ on the amazon.com marketplace in canada (“license agreement”).
SPRC Ratings Summary
SPRC Quant Ranking